Evidence map›Paper›PMID 28718993›Full record

ArticleJournal of neuroimaging : official journal of the American Society of Neuroimaging2018

Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.

Mojgan Hojjati, Chaitra Badve, Vasant Garg, Curtis Tatsuoka, Lisa Rogers, Andrew Sloan, Peter Faulhaber, Pablo R Ros, Leo J Wolansky

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. [Neuroradiology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Neuro-oncology practice · 2021
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mojgan HojjatiDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH.ORCID 0000-0001-6720-1761
Chaitra BadveDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Vasant GargDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Curtis TatsuokaDepartment of Neurology (Epidemiology), Case Western Reserve University, Cleveland, OH.
Lisa RogersDepartment of Neurology, Neuro-oncology Program, University Hospitals Cleveland Medical Center, Cleveland, OH.
Andrew SloanDepartment of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH.
Peter FaulhaberDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Pablo R RosDepartment of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Leo J WolanskyDepartment of Diagnostic Imaging, University of Connecticut School of Medicine, Farmington, CT.
University Hospitals of Cleveland · USCase Western Reserve University · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTo compare the utility of quantitative PET/MRI, dynamic susceptibility contrast (DSC) perfusion MRI (pMRI), and PET/CT in differentiating radiation necrosis (RN) from tumor recurrence (TR) in patients with treated glioblastoma multiforme (GBM).

methodsThe study included 24 patients with GBM treated with surgery, radiotherapy, and temozolomide who presented with progression on imaging follow-up. All patients underwent PET/MRI and pMRI during a single examination. Additionally, 19 of 24 patients underwent PET/CT on the same day. Diagnosis was established by pathology in 17 of 24 and by clinical/radiologic consensus in 7 of 24. For the quantitative PET/MRI and PET/CT analysis, a region of interest (ROI) was drawn around each lesion and within the contralateral white matter. Lesion to contralateral white matter ratios for relative maximum, mean, and median were calculated. For pMRI, lesion ROI was drawn on the cerebral blood volume (CBV) maps and histogram metrics were calculated. Diagnostic performance for each metric was assessed using receiver operating characteristic curve analysis and area under curve (AUC) was calculated.

resultsIn 24 patients, 28 lesions were identified. For PET/MRI, relative mean ≥ 1.31 resulted in AUC of .94 with both sensitivity and negative predictive values (NPVs) of 100%. For pMRI, CBV max ≥3.32 yielded an AUC of .94 with both sensitivity and NPV measuring 100%. The joint model utilizing r-mean (PET/MRI) and CBV mode (pMRI) resulted in AUC of 1.0.

conclusionOur study demonstrates that quantitative PET/MRI parameters in combination with DSC pMRI provide the best diagnostic utility in distinguishing RN from TR in treated GBMs.

Indexed as

AdultAgedAged, 80 and overBrainBrain NeoplasmsDiagnosis, DifferentialDisease ProgressionFemaleFluorodeoxyglucose F18GlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedNecrosisNeoplasm Recurrence, LocalFluorodeoxyglucose F18DSC-pMRIGlioblastomaPET/MRIRNTR

Identifiers

PMID28718993
PMCPMC5811794
OpenAlexW2736860736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.